Lisa Cook sues Trump over firing attempt, emergency hearing set
Investing.com - Eli Lilly’s (NYSE:LLY) oral weight loss drug orforglipron demonstrated unexpectedly strong performance in patients with both obesity and type 2 diabetes, according to a new research note from William Blair. The pharmaceutical giant, currently valued at $641.89 billion and maintaining a robust 82.64% gross profit margin, continues to strengthen its position in the weight management market.
The investment firm highlighted that orforglipron "outperformed investor expectations" in this patient population, which it describes as "the higher-risk and more difficult-to-treat population." William Blair noted that approximately 25% of overweight or obese individuals also have type 2 diabetes. According to InvestingPro data, Eli Lilly’s strong market position is reflected in its impressive 36.83% revenue growth over the last twelve months.
Based on analysis of three Phase III studies, William Blair believes the drug showed its "highest competitive advantage in diabetes," a condition affecting roughly 15% of the U.S. adult population.
The research note emphasized that type 2 diabetes patients often manage multiple comorbid conditions such as hypertension or dyslipidemia with oral medications, creating a potential advantage for Lilly’s oral formulation.
"It is therefore our opinion that orforglipron could be seamlessly incorporated into patients’ daily routines, thereby encouraging uptake," William Blair concluded in its assessment of the drug’s market potential.
In other recent news, Eli Lilly has announced positive results from its Phase 3 trial of the oral GLP-1 drug orforglipron, which met all primary and secondary endpoints for adults with obesity or overweight and type 2 diabetes. Participants taking the highest dose experienced significant weight loss over 72 weeks, paving the way for global regulatory submissions this year. In addition, BofA Securities has reiterated its Buy rating on Eli Lilly, highlighting a projected revenue growth of approximately 35% in 2025, which significantly surpasses the industry average.
Furthermore, Eli Lilly has entered into a clinical supply agreement with Immuneering Corp to evaluate Immuneering’s lead product candidate in combination with Eli Lilly’s second-generation KRAS G12C inhibitor in a planned Phase 2 clinical trial. This study will focus on patients with advanced or metastatic KRAS G12c-mutant non-small cell lung cancer. In another development, Anne White, executive vice president and president of Lilly Neuroscience, is set to retire at the end of 2025 after a 30-year tenure with the company. An internal and external search for her successor is underway.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.